Showing results (151-160 of 174) with videos related to
Sort By:
Pageof 18
The Lancet. Diabetes & Endocrinology|January 30, 2026
Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trialAlbert Wiegman, Amy L Peterson, Eric Bruckert, et al.Journal of Clinical Lipidology|March 21, 2020
Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trialPatrick M Moriarty, Paul D Thompson, Christopher P Cannon, et al.Journal of Clinical Lipidology|October 9, 2022
Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemiaDaniel Gaudet, Andrea Ruzza, Ian Bridges, et al.Journal of Clinical Lipidology|December 22, 2015
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trialPatrick M Moriarty, Paul D Thompson, Christopher P Cannon, et al.Journal of Clinical Lipidology|May 12, 2018
Clinical and biochemical features of different molecular etiologies of familial chylomicronemiaRobert A Hegele, Amanda J Berberich, Matthew R Ban, et al.The Canadian Journal of Cardiology|December 3, 2014
Canadian Cardiovascular Society position statement on familial hypercholesterolemia, Jacques Genest, Robert A Hegele, et al.Atherosclerosis|October 2, 2018
Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registryLiam R Brunham, Isabelle Ruel, Etienne Khoury, et al.European Journal of Preventive Cardiology|October 19, 2023
Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatmentRaul D Santos, Andrea Ruzza, Bei Wang, et al.Atherosclerosis|January 8, 2026
Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemiaRobert S Rosenson, Eliot A Brinton, Daniel Gaudet, et al.The New England Journal of Medicine|March 17, 2015
Efficacy and safety of alirocumab in reducing lipids and cardiovascular eventsJennifer G Robinson, Michel Farnier, Michel Krempf, et al.Pageof 18